Coronary artery disease: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• PCSK9 14
• SGLT2 12
• APOE 0
• GLP-1 4
• NLRP3 1
• PPAR 0
• IL-6 2
• NRF2 0
• CD40 0
• AKT 0
• VEGF 0
• TNF 1
• PI3K 0
• SIRT1 0
• TP53 0
• HMGB1 0
• STAT3 0
• TLR4 0
• HIF-1 0
• AMPK 0
• IL-1 1
• JAK 0
• MMP-9 0
• STING 1
• ACE2 0
• ERK 0
• GIP 1
• mTOR 0
• PD-1 0
• BDNF 0
• COX-2 0
• CXCR4 1
• DPP-4 0
• FGFR 0
• HER2 0
• IL-17 1
• MAPK 0
• PTEN 0
• TREM2 0
• YAP 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APP 0
• BACE1 0
• BCL-2 0
• BRAF 0
• BTK 0
• CCR5 0
• CGRP 0
• CTLA-4 0
• CTNNB1 0
• EZH2 0
• FOXP3 0
• FTO 0
• G6PD 0
• GPX4 0
• HSP90 0
• IL-4 1
• LRRK2 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unmasking the Perivascular Adipose Tissue's Role in Diabetic Vascular Disease From Molecular Clues to Clinical Impact (IMAPERFAT)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €236,340· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Delineating and eradicating cardiovascular inflammageing (DEFLAME)

  Technische Universiteit Eindhoven· Eindhoven, Netherlands· EU contribution €2,500,000· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Predicting Female-Predominant Cardiovascular Dissections via multi-scale Hormonal, Imaging, and Biomechanical Integration (DISSEX)

  Aarhus Universitet· Aarhus C, Denmark· EU contribution €1,499,585· until Feb 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  DEVELOPMENT OF A NANOHYBRID SYSTEM BASED WEARABLE MICROFLUIDIC PHOTOELECTROCHEMICAL SENSOR FOR THE ON-DEMAND cTnI DETECTION (NANOPEC)

  Kauno Technologijos Universitetas· Kaunas, Lithuania· EU contribution €196,976· until Jan 2029· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Socio-Environmental Determinants of Health in Small States (SEEDS)

  Universita Ta Malta· Msida, Malta· EU contribution €205,314· until Jan 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Holistic Efficient Arrhythmic Risk Twinning for Post-MI Stratification (HEART-TWIN)

  Universidad Pompeu Fabra· Barcelona, Spain· EU contribution €209,915· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Robotic Endovascular Access for Critical Treatment (REACT)

  Nanoflex Robotics AG· Glattbrugg, Switzerland· EU contribution €2,498,972· until Sept 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  CAR-engineered Cell therapy for Cardiovascular diseases (CARDIO)

  Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat· Wurzburg, Germany· EU contribution €6,940,517· until Sept 2030· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Strengthening secondary prevention of ischemic heart disease in rural Ukraine and Bulgaria: the SPIDR Consortium

  London School of Hygiene and Tropical Medicine Royal Charter· London, United Kingdom· EU contribution €3,854,644· until Aug 2031· 7 countries

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  From Naked Mole-Rat to Preclinical Pig: Advancing a Regenerative Factor for Myocardial Infarction (NEWHEART)

  Klinikum Der Universitaet Zu Koeln· Koeln, Germany· EU contribution €150,000· until Feb 2028

10 of 72 running projects, newest first. Listed amounts together: €236.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 14
• Organoids 1
• Mendelian Randomization Analysis 136
• CRISPR-Cas Systems 4
• Gene Expression Profiling 48
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 6
• Proteomics 68
• Metabolomics 41
• Mass Spectrometry 5
• Flow Cytometry 26
• Immunohistochemistry 12
• Positron-Emission Tomography 64
• Magnetic Resonance Imaging 66
• Machine Learning 161
• Deep Learning 85
• Cohort Studies 405
• Genome-Wide Association Study 163

• Adjusting for Medication Use in GWAS and Its Impact on Mendelian Randomisation Analyses: An Example of Systolic Blood Pressure in UK Biobank.

  Genet Epidemiol, Dec 2026

• Identification of genetically supported candidate therapeutic targets for angina pectoris using mendelian randomization.

  Medicine (Baltimore), Oct 2026

• Gut microbiota, sleep and coronary artery disease: A Mendelian randomization study.

  Medicine (Baltimore), Oct 2026

• Blood proteome-wide Mendelian randomization reveals molecular pleiotropy in coronary artery disease.

  Atherosclerosis, Oct 2026

• Genetic factor analysis for characterizing phenome-wide patterns of genetic pleiotropy.

  Nat Genet, Sept 2026

• Antihypertensive Treatment and Risk of Metabolic Associated Fatty Liver Disease: A Drug-Target Mendelian Randomization.

  Hypertension, Sept 2026

• Exploring the role of gut microbiota in coronary atherosclerosis through lipoprotein-mediated cholesterol transport and distribution: A Mendelian randomization analysis.

  Medicine (Baltimore), Sept 2026

• The Omnicausal Model Reveals the Highly Polyfactorial Nature of Complex Diseases.

  Genet Epidemiol, Sept 2026

• Context-Stratified Mendelian Randomization: Exploiting Regional Exposure Variation to Explore Causal Effect Heterogeneity and Nonlinearity.

  Stat Med, Sept 2026

• Myeloid Dendritic Cell Counts and Coronary Heart Disease: a Bidirectional Mendelian Randomization Study.

  Clin Lab, Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.